SVS Stock Overview
SVAS Biosana S.p.A. engages in the production and marketing of medical devices worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
Svas Biosana S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.00 |
| 52 Week High | €8.55 |
| 52 Week Low | €6.48 |
| Beta | 0.88 |
| 1 Month Change | -3.45% |
| 3 Month Change | -6.67% |
| 1 Year Change | -14.63% |
| 3 Year Change | -43.73% |
| 5 Year Change | n/a |
| Change since IPO | -51.69% |
Recent News & Updates
Shareholder Returns
| SVS | IT Medical Equipment | IT Market | |
|---|---|---|---|
| 7D | -2.8% | 0.9% | 1.0% |
| 1Y | -14.6% | -1.9% | 6.3% |
Return vs Industry: SVS underperformed the Italian Medical Equipment industry which returned -3% over the past year.
Return vs Market: SVS underperformed the Italian Market which returned 4.5% over the past year.
Price Volatility
| SVS volatility | |
|---|---|
| SVS Average Weekly Movement | 4.5% |
| Medical Equipment Industry Average Movement | 5.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IT Market | 8.4% |
| 10% least volatile stocks in IT Market | 3.3% |
Stable Share Price: SVS has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: SVS's weekly volatility (4%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 327 | Umberto Perillo | svas.it |
SVAS Biosana S.p.A. engages in the production and marketing of medical devices worldwide. The company offers incontinence aids, traditional dressings, and personal care products for use in incontinence devices, dressings, and personal care product applications. It also offers operating packs, medical devices, infusion and aspiration, linen, advanced dressings, and lubricating gels that are used in haemodynamic, heart surgery, anaesthesia, and critical care applications.
Svas Biosana S.p.A. Fundamentals Summary
| SVS fundamental statistics | |
|---|---|
| Market cap | €37.79m |
| Earnings (TTM) | €5.45m |
| Revenue (TTM) | €123.79m |
6.9x
P/E Ratio0.3x
P/S RatioIs SVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SVS income statement (TTM) | |
|---|---|
| Revenue | €123.79m |
| Cost of Revenue | €90.18m |
| Gross Profit | €33.60m |
| Other Expenses | €28.15m |
| Earnings | €5.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.01 |
| Gross Margin | 27.15% |
| Net Profit Margin | 4.40% |
| Debt/Equity Ratio | 107.8% |
How did SVS perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yieldn/a
Payout RatioDoes SVS pay a reliable dividends?
See SVS dividend history and benchmarks| Svas Biosana dividend dates | |
|---|---|
| Ex Dividend Date | Jun 09 2025 |
| Dividend Pay Date | Jun 11 2025 |
| Days until Ex dividend | 46 days |
| Days until Dividend pay date | 48 days |
Does SVS pay a reliable dividends?
See SVS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/23 08:33 |
| End of Day Share Price | 2025/04/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Svas Biosana S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simone Mieli | TPICAP Midcap |
| Mathias Paladino | TPICAP Midcap |